Physician profile
Barry Lobovits
NPI 1801890165
$8,837.23
in general payments reported to CMS, 2019-2025
43 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 85% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088 · 2020: $1,065 · 2021: $1,726 · 2022: $1,409 · 2023: $1,244 · 2024: $1,095 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,548.24 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,198.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,015.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $854.57 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $665.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $571.40 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $457.42 | 2019-2024 | Camzyos, Eliquis |
| Exact Sciences Corporation | $400.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $393.72 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $291.55 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $275.05 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $267.26 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $259.76 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $257.16 | 2022 | |
| Merck Sharp & Dohme LLC | $208.33 | 2021-2023 | Belsomra, Steglatro |
| Amgen INC. | $190.45 | 2019-2024 | Evenity |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Lobovits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.